Project Grant R16CA315530
Award Date 8/20/26
Completion Date 7/31/30
Dollars Obligated $150K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70125, USA
Similar Awards
- The National Cancer Institute awarded Health Research, Inc. Roswell Park Division $719,951 on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms underlying lung cancer lineage plasticity and adaptive resistance to EGFR tyrosine kinase inhibitor therapy. The research addresses a gap in understanding how transcriptional plasticity—reversible and dynamic gene expression adaptations—accelerates acquired EGFR TKI resistance in EGFR-mutant lung...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas Health Science Center at Houston $635,948 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate phospholipase D1 (PLD1) and transferrin receptor 1 (TFR1) as therapeutic targets in chromosome 3q-amplified non-small cell lung cancer. The project will define the mechanisms by which PLD1 promotes NSCLC progression and tumor microenvironment...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $681,200 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and test strategies to overcome that resistance. The project tests whether CD74-positive drug-tolerant persister cells drive acquired resistance to osimertinib and other third-generation EGFR tyrosine kinase inhibitors. The...
- The National Cancer Institute awarded The University of Chicago $588,289 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize how BH3-mimetic drugs alter T cell function through BCL-2 family protein-protein interactions, with the goal of informing T cell-based cancer therapies. The project investigates the non-apoptotic immunomodulatory effects of BH3-mimetic compounds on human T cells used in adoptive cell therapy. While BH3 mimetics are known to induce...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded $831,988 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds a five-year project investigating the role of ASAH1-driven ceramide metabolism in Epstein Barr Virus-driven B-cell transformation under germinal center hypoxia. The research addresses...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $388,546 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how chromosome 3q amplification drives non-small cell lung cancer progression through Golgi-dependent secretory pathways and to develop manganese-based targeted therapy for this genetically defined cancer subset. The award funds research into the molecular mechanisms by which two chromosome 3q-encoded...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Institutes of Health National Cancer Institute awarded Baylor College of Medicine $411,400 on August 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of action and evaluate efficacy of compounds that target convergent oncogenic pathways activated during osimertinib resistance in EGFR-mutated non-small cell lung cancer. The research will examine how these compounds reverse osimertinib resistance and assess their efficacy in combination...